SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Result of AGM

31 Dec 2025 12:30

RNS Number : 3360N
Frontier IP Group plc
31 December 2025
 

RNS

AIM: FIPP

31 December 2025

 

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Result of Annual General Meeting

 

Frontier IP, a specialist in commercialising intellectual property, announces that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed with the table below summarising proxy votes received.

 

 RESOLUTIONS

NO OF VOTES FOR

% OF VOTES CAST (EXCLUDING VOTES WITHELD)

NO OF VOTES AGAINST

% OF VOTES CAST (EXCLUDING VOTES WITHELD)

TOTAL VOTES CAST (EXCLUDING VOTES WITHHELD)

NO OF VOTES WITHHELD

ORDINARY

1. To receive the audited consolidated financial statements of the Company and its subsidiaries for the year ended 30 June 2025, together with the reports of the Directors and the Auditor thereon.

31,470,839

99.98%

6,679

0.02%

31,477,518

271,131

2. To approve the report of the Board to the members on directors' remuneration for the year ended 30 June 2025.

31,381,107

99.4%

197,911

0.6%

31,579,018

169,631

3. To re-appoint Neil Crabb as a Director of the Company and, being eligible, is offering himself for reappointment.

31,424,089

99.5%

158,367

0.5%

31,582,456

166,193

4. To re-appoint Nigel Grierson as a Director of the Company and, being eligible, is offering himself for reappointment.

31,424,089

99.5%

158,367

0.5%

31,582,456

166,193

5. To re-appoint David Holbrook as a Director of the Company and, being eligible, is offering himself for reappointment.

31,424,089

99.5%

158,367

0.5%

31,582,456

166,193

6. To re-appoint Professor Dame Julia Elizabeth King, Baroness Brown of Cambridge as a Director of the Company and, being eligible, is offering herself for reappointment.

31,382,089

99.4%

200,367

0.6%

31,582,456

166,193

7. To re-appoint Jacqueline McKay as a Director of the Company and, being eligible, is offering herself for reappointment.

31,382,089

99.4%

200,367

0.6%

31,582,456

166,193

8. To re-appoint Joanne Stent as a Director of the Company and, being eligible, is offering herself for reappointment

31,382,089

99.4%

200,367

0.6%

31,582,456

166,193

9. To re-appoint Matthew White as a Director of the Company and, being eligible, is offering himself for reappointment.

31,367,089

99.4%

200,367

0.6%

31,567,456

181,193

10. To re-appoint BDO LLP as auditor of the Company to hold office until the conclusion of the next general meeting at which financial statements are laid before shareholders.

31,479,586

99.98%

7,507

0.02%

31,487,093

261,556

11. To authorise the Directors to determine the auditor's remuneration

31,598,955

99.98%

6,679

0.02%

31,605,634

143,015

12. To authorise the directors to allot shares

31,368,151

99.2%

260,192

0.8%

31,628,343

120,306

SPECIAL

13. Authority to disapply pre-emption rights in connection with the allotment and issue of equity securities for cash in relation to (i) share option schemes; (ii) rights issue or similar offer; (iii) allotment of equity securities up to 10% of the issued share capital; or (iv) to the allotment of equity securities up to a nominal amount equal to 20%, such authority to be used only for the purposes of making a follow-on offer which the Board of the Company determines to be of a kind contemplated by paragraph 3 of Section 2B of the Statement of Principles on Disapplying Pre-Emption Rights.

28,856,430

91.3%

2,756,913

8.7%

31,613,343

135,306

14. Authority to disapply pre-emption rights to allot equity securities for cash.

31,140,405

98.5%

487,938

1.5%

31,628,343

120,306

15. Authority to purchase own shares on market.

17,550,355

99.6%

68,284

0.4%

17,618,639

14,130,010

 

 

Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution.

 

ENQUIRIES

 

Frontier IP Group Plc

Neil Crabb, Chief Executive

 

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

neil@frontierip.co.uk

 

M: 07464 546 025

andrew.johnson@frontierip.co.uk

 

Allenby Capital Limited (Nominated Adviser)

Nick Athanas

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Charles Leigh-Pemberton / James Fischer

T: 0207 496 3000

 

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

 

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGTBBTTMTMJBBA
Date   Source Headline
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding
31st Mar 20251:02 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSUnaudited Half Year Results
24th Mar 20257:00 amRNSCamGraphIC secures €25 million in Series A funding
18th Mar 20257:00 amRNS-RPulsiv wins PSMA’s Global Energy Efficiency Award
25th Feb 20257:00 amRNS-RGraphEnergyTech collaboration & Innovate UK grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.